Want to see IN:JHS full AI Analyst Report?
Top Page
JHS Svendgaard Laboratories Limited
(JHS)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹8.50
▲(14.71% Upside)
Action:Reiterated
Date:10/06/26
The score is held back primarily by weak financial performance—persistent losses and inconsistent/negative operating and free cash flow—despite a low-leverage balance sheet. Technicals provide meaningful support with a clear uptrend and positive momentum. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Low leverage and balance-sheet stability
Very low leverage and a substantial equity base reduce solvency pressure and preserve financial flexibility. This gives JHS more capacity to withstand operating volatility and support manufacturing activity without relying heavily on debt or refinancing.
Negative Factors
Persistent losses and negative operating earnings
Ongoing net losses and negative operating earnings show that the business has not yet converted manufacturing activity into sustainable shareholder returns. Continued unprofitability can restrict reinvestment, weaken internal funding capacity, and increase execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and balance-sheet stability
Very low leverage and a substantial equity base reduce solvency pressure and preserve financial flexibility. This gives JHS more capacity to withstand operating volatility and support manufacturing activity without relying heavily on debt or refinancing.
Read all positive factors
JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹719.35M
Dividend Yield14.74%
Average Volume (3M)62.84K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth19.41%
EPS Growth90.12%
CountryIN
Employees235
SectorGeneral
Sector StrengthN/A
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.22
Shares Outstanding87,405,770
10 Day Avg. Volume13,596
30 Day Avg. Volume62,843
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)0.33
Price to Sales (P/S)0.56
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JHS Svendgaard Laboratories Limited Business Overview & Revenue Model
Company Description
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive prod...
How the Company Makes Money
JHS primarily makes money by manufacturing and supplying finished consumer products (notably oral care products such as toothpaste) to customers and receiving revenue from the sale of those goods. A key revenue stream is typically contract manufac...
JHS Svendgaard Laboratories Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.09B | 1.02B | 919.97M | 698.06M | 840.82M | 854.91M |
| Gross Profit | 274.58M | 177.22M | 309.55M | 203.55M | 165.45M | 201.68M |
| EBITDA | 47.50M | 60.64M | -39.92M | 33.78M | -163.82M | 85.45M |
| Net Income | -18.87M | -19.22M | -197.44M | -40.58M | -175.17M | -40.52M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 2.15B | 2.01B | 1.97B | 2.28B | 2.22B |
| Cash, Cash Equivalents and Short-Term Investments | 191.00M | 191.00M | 200.16M | 94.56M | 386.51M | 80.19M |
| Total Debt | 0.00 | 148.51M | 64.58M | 51.29M | 155.09M | 61.82M |
| Total Liabilities | -1.75B | 405.49M | 284.41M | 271.70M | 543.87M | 269.46M |
| Stockholders Equity | 1.75B | 1.75B | 1.73B | 1.70B | 1.74B | 1.86B |
Cash Flow | ||||||
| Free Cash Flow | -29.85M | -148.91M | -157.11M | -401.17M | 89.43M | -158.75M |
| Operating Cash Flow | -29.85M | -20.97M | -51.78M | -85.84M | 232.86M | -91.36M |
| Investing Cash Flow | 92.77M | -130.38M | -220.18M | -217.34M | 96.77M | -46.97M |
| Financing Cash Flow | 38.02M | 121.43M | 232.97M | 21.74M | -9.00M | -16.72M |
JHS Svendgaard Laboratories Limited Technical Analysis
Negative
7.41
Price Trends
8.85
Negative
8.32
Negative
8.80
Negative
Market Momentum
-0.13
Positive
41.78
Neutral
5.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 7.41 is below the 20-day moving average (MA) of 9.55, below the 50-day MA of 8.85, and below the 200-day MA of 8.80, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 5.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.
JHS Svendgaard Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹162.81B | 21.51 | ― | 3.77% | 2.82% | -8.52% | |
67 Neutral | ₹436.67B | 32.02 | ― | 2.99% | 8.72% | 2.71% | |
65 Neutral | ₹638.62B | 32.18 | ― | 2.29% | 7.40% | 10.63% | |
63 Neutral | ₹147.38B | 59.07 | ― | 0.66% | 21.08% | 237.04% | |
59 Neutral | ₹848.93B | 44.30 | ― | 2.40% | 9.22% | 3.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹719.35M | -36.05 | ― | 14.74% | 19.41% | 90.12% |
* General Sector Average
IN:JHS
JHS Svendgaard Laboratories Limited
8.23
-5.08
-38.17%
IN:COLPAL
Colgate-Palmolive (India) Limited
1,605.50
-577.64
-26.46%
IN:DABUR
Dabur India Limited
360.00
-133.70
-27.08%
IN:EMAMILTD
Emami Limited
370.80
-170.29
-31.47%
IN:GODREJCP
Godrej Consumer Products Limited
829.60
-264.57
-24.18%
IN:HONASA
Honasa Consumer Limited
452.05
181.94
67.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.